ASCELIA

AN ONCOLOGY-DEDICATED DRUG DEVELOPMENT COMPANY

Magnus Corfitzen, CEO presenting at Redeye event in Malmö 12 Sep 2019

Download our Ascelia Pharma Fact sheet

Lead candidate Mangoral (Phase III) is an MRI imaging drug being developed for detection and localization of liver metastases.

Oncoral (phase II ready) is a novel tablet-based irinotecan formulation, intended for treatment of advanced gastric (stomach) cancer.

• May 6 @ 11:00 - 13:00

  Annual General Meeting 2020

• May 13 @ 08:00

  Interim financial report Q1 2020 (Jan-Mar)

• June 2 @ 08:00 - 17:00

  Redeye Growth Day

• August 20 @ 08:00

  Half-year financial report 2020 (Jan-Jun)

• November 5 @ 08:00

  Interim financial report 9M 2020 (Jan-Sep)

• 2020-03-31Change in number of shares and votes in Ascelia Pharma AB
• 2020-03-30Leading Ascelia Pharma through the Covid-19 period
• 2020-03-05Analysguiden/Carlsquare updates its view on Ascelia Pharma and raises target share price
• 2020-03-02Issue and repurchase of series C shares for share saving program
• 2020-02-20Vator Securities: Ascelia Pharma: A rocket roll out is the key to success